Continuous remission in an infant with chest wall malignant rhabdoid tumor after relapse

Hosoi, Hajime; Iehara, Tomoko; Tsuchiya, Kunihiko; Misawa, Akiko; Miyaji, Masao; Yagyu, Shigeki; Koizumi, Makoto; Tokiwa, Kazuyasu; Iwai, Naoharu; Yanagisawa, Akio; Sugimoto, Tohru

doi:10.1016/j.jpedsurg.2007.07.003

Cited by 7 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiation therapy is a key component for treatment of renal tumors with unfavorable histology, but the role of irradiation in treatment of MRT is yet to be determined. There was a report suggesting the benefits of irradiation, 9 while some previous reports failed to show survival advantage of irradiated patients 2,3 . In our case, ascites containing tumor cells appeared soon after abdominal irradiation.…”

Section: Discussionmentioning

confidence: 38%

“…However, relapse is still a major problem in stage IV MRT, and prognosis of relapsed MRT is dismal. Although a few studies reported survival from relapsed MRT, 4,9 there is no report about a long‐term survivor of relapsed MRT that was metastatic at diagnosis. Here we report a case of a long‐term survivor of stage IV MRT, which relapsed after high‐dose chemotherapy.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Long‐term survivor of relapsed stage IV malignant rhabdoid tumor of the kidney

Kato

Koh²,

Oshima³

et al. 2013

Pediatrics International

View full text Add to dashboard Cite

The prognosis for metastatic malignant rhabdoid tumor (MRT) is poor, and metastatic (stage IV) MRT was resistant to conventional treatment, with less than 20% of cure rate. Moreover, there have been no reports of patients who have survived relapsed stage IV MRT. Here we report a long-term survivor of relapsed MRT with lung metastasis at diagnosis. He was diagnosed as MRT of the kidney at 5-month-old. After resection of the renal tumor, he was treated with ICE (ifosfamide, carboplatin, and etoposide), total abdominal irradiation 10.8 Gy and high-dose chemotherapy using thiotepa and melphalan. Six months after initial treatment, a relapse in the lung was detected, and he received chemotherapy including doxorubicin/pirarubicin for 78 weeks. He is alive at five years of follow up, without any evidence of disease. Our report suggests the important role of anthracycline in treatment of MRT.

show abstract

Section: Discussionmentioning

confidence: 38%

mentioning

confidence: 99%

Long‐term survivor of relapsed stage IV malignant rhabdoid tumor of the kidney

Kato

Koh²,

Oshima³

et al. 2013

Pediatrics International

View full text Add to dashboard Cite

show abstract

“…Imaging serves to define the extent of disease, which is vital since adequate resection provides the best chance for control of disease. Aggressive chemotherapy and radiotherapy have improved short-term survival [8], but overall survival remains dismal. Chemotherapeutic agents used for rhabdoid tumors include actinomycin D, vincristine, cisplatinum, adriamycin, cyclophosphamide, ifosfamide, and etoposide, with no definite advantage of one over the other [8].…”

Section: Discussionmentioning

confidence: 99%

Malignant Rhabdoid Tumour of the Perineum in an Adult—A Rare Presentation

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Malignant rhabdoid tumor (MRT) is a rare pediatric cancer that primarily occurs in the kidney, brain, and soft tissues (Hosoi et al, ; Reinhard et al, ; Sultan et al, ). Although various combinations of conventional therapies have been evaluated in clinical trials, no significant improvement in overall survival has been observed and the 5‐year overall survival remains only approximately 30% (Tomlinson et al, ; Reinhard et al, ; Sultan et al, ).…”

mentioning

confidence: 99%

A NOXA/MCL‐1 Imbalance Underlies Chemoresistance of Malignant Rhabdoid Tumor Cells

Ouchi

Kuwahara

Iehara

et al. 2016

Journal Cellular Physiology

Self Cite

View full text Add to dashboard Cite

Malignant rhabdoid tumor (MRT) is a rare aggressive pediatric cancer characterized by inactivation of SNF5, a core subunit of SWI/SNF complexes. Previously, we showed that SNF5 contributes to transcriptional activation of NOXA, a pro-apoptotic protein that binds and inhibits the anti-apoptotic protein MCL-1. In this study, we found that NOXA expression was downregulated in MRT cell lines as well as in clinical MRT samples and that ectopically expressed NOXA bound MCL-1 and increased the sensitivity of MRT cell lines to doxorubicin (DOX) by promoting apoptosis. Consistent with this finding, knockdown of MCL-1 in MRT cell lines induced apoptosis and increased DOX sensitivity in MRT cells, and the MCL-1 inhibitor TW-37 synergized with DOX to induce MRT cell death. Our results suggest that modulation of the NOXA/MCL-1 pathway may be a potential strategy for the treatment of patients with MRT. J. Cell. Physiol. 231: 1932-1940, 2016. © 2015 Wiley Periodicals, Inc.

show abstract

Continuous remission in an infant with chest wall malignant rhabdoid tumor after relapse

Cited by 7 publications

References 10 publications

Long‐term survivor of relapsed stage IV malignant rhabdoid tumor of the kidney

Long‐term survivor of relapsed stage IV malignant rhabdoid tumor of the kidney

Malignant Rhabdoid Tumour of the Perineum in an Adult—A Rare Presentation

A NOXA/MCL‐1 Imbalance Underlies Chemoresistance of Malignant Rhabdoid Tumor Cells

Contact Info

Product

Resources

About